James Posey

7.9k total citations · 1 hit paper
66 papers, 2.7k citations indexed

About

James Posey is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, James Posey has authored 66 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 14 papers in Surgery. Recurrent topics in James Posey's work include Colorectal Cancer Treatments and Studies (15 papers), Pancreatic and Hepatic Oncology Research (14 papers) and Lung Cancer Treatments and Mutations (9 papers). James Posey is often cited by papers focused on Colorectal Cancer Treatments and Studies (15 papers), Pancreatic and Hepatic Oncology Research (14 papers) and Lung Cancer Treatments and Mutations (9 papers). James Posey collaborates with scholars based in United States, Germany and Canada. James Posey's co-authors include Matthew H. Kulke, Heinz‐Josef Lenz, Neal J. Meropol, Charles S. Fuchs, Keith Stuart, David P. Ryan, Mansoor N. Saleh, Charles M. Baum, Joel Picus and Emily K. Bergsland and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and Cancer.

In The Last Decade

James Posey

64 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial

2009 487 citations James C. Yao, Catherine Lombard‐Bohas et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by James Posey

Since Specialization

Citations

This map shows the geographic impact of James Posey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Posey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Posey more than expected).

Fields of papers citing papers by James Posey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Posey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Posey. The network helps show where James Posey may publish in the future.

Co-authorship network of co-authors of James Posey

This figure shows the co-authorship network connecting the top 25 collaborators of James Posey. A scholar is included among the top collaborators of James Posey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Posey. James Posey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Early outcomes of MR-guided SBRT for patients with recurrent pancreatic adenocarcinoma 2024 ·Radiation Oncology ·(unknown), (unknown), (unknown), Pramila R. Anné, Karen Mooney, Maria Werner‐Wasik, (unknown), James Posey, Daniel Lin, Atrayee Basu Mallick, Harish Lavu, Babar Bashir, Charles J. Yeo, Adam C. Mueller	1
2	Genomic characterization of early-stage hepatocellular carcinoma patients with Hepatitis B using circulating tumor DNA 2023 ·Clinics and Research in Hepatology and Gastroenterology ·(unknown), Rui Luo, Zhong Ye, Qiang Wei, Ho Bae, Hee‐Soon Juon, H W Hann, James Posey, Chun Wang	5
3	Sonoporation for disrupting the pancreatic cancer microenvironment to enhance chemotherapy delivery and improve outcomes. 2023 ·Journal of Clinical Oncology ·James Posey, Priscilla Machado, John R. Eisenbrey, Babar Bashir, Patrick Mille, Atrayee Basu Mallick, (unknown), Spiros Kotopoulis, (unknown), (unknown), (unknown), (unknown), (unknown), Flemming Forsberg	1
4	Repurposing the FDA-approved anthelmintic pyrvinium pamoate for pancreatic cancer treatment: study protocol for a phase I clinical trial in early-stage pancreatic ductal adenocarcinoma 2023 ·BMJ Open ·(unknown), Christopher W. Schultz, Benjamin E. Leiby, (unknown), Tsin Wen Yeo, James Posey, Wilbur B. Bowne, Charles J. Yeo, Jonathan R. Brody, Harish Lavu, Avinoam Nevler	6
5	Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A National Cancer Database analysis 2021 ·European Journal of Cancer ·(unknown), Chun Wang, Steven J. Cohen, Jordan M. Winter, James Posey, Charles J. Yeo, (unknown)	15
6	Racial Disparities in Rates of Surgery for Esophageal Cancer: a Study from the National Cancer Database 2020 ·Journal of Gastrointestinal Surgery ·Samantha L. Savitch, Tyler R. Grenda, (unknown), Scott W. Cowan, James Posey, Edith P. Mitchell, Steven J. Cohen, Charles J. Yeo, Nathaniel R. Evans	32
7	Abemaciclib Is Effective Against Pancreatic Cancer Cells and Synergizes with HuR and YAP1 Inhibition 2019 ·Molecular Cancer Research ·(unknown), Christopher W. Schultz, Aditi Jain, (unknown), (unknown), Austin Goetz, Chunhua Xi, Gloria H. Su, Liang Xu, James Posey, Wei Jiang, Charles J. Yeo, Talia Golan, Michael J. Pishvaian, Jonathan R. Brody	44
8	Multiregion whole-exome sequencing of matched primary and metastatic tumors revealed genomic heterogeneity and suggested polyclonal seeding in colorectal cancer metastasis 2017 ·Annals of Oncology ·Qiang Wei, (unknown), Xue Zhong, (unknown), (unknown), Ronald E. Myers, (unknown), (unknown), (unknown), Scott A. Waldman, X. Chen, James Posey, (unknown), Bing‐Hua Jiang, Lifang Hou, (unknown), Yu Sun, Jinliang Xing, Bian Li, Huanming Yang	76
9	A comparison of 12-gene colon cancer assay gene expression in African American and Caucasian patients with stage II colon cancer 2016 ·BMC Cancer ·Rangaswamy Govindarajan, James Posey, Calvin Chao, Ruixiao Lu, Trafina Jadhav, (unknown), Awais Javed, Fade Mahmoud, Raymond U. Osarogiagbon, Upender Manne	12
10	RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long‐term survival and reveals a role forANGPTL4 2016 ·Molecular Oncology ·Marie K. Kirby, Ryne C. Ramaker, Jason Gertz, Nicholas S. Davis, (unknown), Patsy G. Oliver, Katherine C. Sexton, Edward Greeno, John D. Christein, Martin J. Heslin, James Posey, William E. Grizzle, Selwyn M. Vickers, Donald J. Buchsbaum, Sara J. Cooper, R Myers	63
11	Pancreatic cancer survivors’ preferences, barriers, and facilitators related to physical activity and diet interventions 2016 ·Journal of Cancer Survivorship ·Anna E. Arthur, (unknown), Wendy Demark‐Wahnefried, John D. Christein, Carlo M. Contreras, James Posey, Selwyn M. Vickers, Robert A. Oster, Laura Q. Rogers	31
12	Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone 2015 ·Journal of Gastrointestinal Cancer ·Andrew M. McDonald, (unknown), (unknown), James Posey, K.S. Keene, John D. Christein, Martin J. Heslin, Tina E. Wood, Rojymon Jacob	6
13	The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases 2013 ·Cancer Chemotherapy and Pharmacology ·Anthony B. El-Khoueiry, James Posey, (unknown), Smitha Krishnamurthi, S. Syed, Georgia Kollia, Ian Walters, Bruce S. Fischer, Eric Masson	3
14	Evaluation of lymph node numbers for adequate staging of Stage II and III colon cancer 2011 ·Journal of Hematology & Oncology ·Chandrakumar Shanmugam, Robert B. Hines, Nirag Jhala, Venkat R. Katkoori, Bin Zhang, James Posey, Harvey L. Bumpers, William E. Grizzle, Isam Eltoum, Gene P. Siegal, Upender Manne	19
15	Phase I Trial of Weekly Tigatuzumab, an Agonistic Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5) 2010 ·Cancer Biotherapy and Radiopharmaceuticals ·Andres Forero‐Torres, Jatin J. Shah, Tina E. Wood, James Posey, (unknown), Catherine Copigneaux, Feng Luo, Slawomir Wojtowicz‐Praga, Ivor Percent, Mansoor N. Saleh	116
16	Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial breakdown → 2009 ·Journal of Clinical Oncology ·James C. Yao, Catherine Lombard‐Bohas, Éric Baudin, Larry K. Kvols, Philippe Rougier, Philippe Ruszniewski, Sakina Hoosen, J. Peter, T Haas, David Lebwohl, Eric Van Cutsem, Matthew H. Kulke, Timothy J. Hobday, Thomas M. O’Dorisio, Manisha H. Shah, Guillaume Cadiot, Gabriele Luppi, James Posey, Bertram Wiedenmann	487
17	Effect of comorbidity and body mass index on the survival of African‐American and Caucasian patients with colon cancer 2009 ·Cancer ·Robert B. Hines, Chandrakumar Shanmugam, John W. Waterbor, Gerald McGwin, Ellen Funkhouser, Christopher S. Coffey, James Posey, Upender Manne	59
18	Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancers 2009 ·Cancer Chemotherapy and Pharmacology ·Afshin Dowlati, James Posey, Ramesh K. Ramanathan, Linda Rath, Pingfu Fu, Amitabh Chak, Smitha Krishnamurthi, Joanna M. Brell, Stephen T. Ingalls, Charles L. Hoppel, Percy Ivy, Scot C. Remick	10
19	Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase I study 2005 ·Anti-Cancer Drugs ·M.C. Dobelbower, Suzanne Russo, Kevin P. Raisch, (unknown), Lisa Clemons, (unknown), James Posey, James A. Bonner	30
20	A Pilot Trial of Vitaxin, A Humanized Anti-Vitronectin Receptor (anti α _v β ₃ ) Antibody in Patients with Metastatic Cancer 2001 ·Cancer Biotherapy and Radiopharmaceuticals ·James Posey, M.B. Khazaeli, (unknown), Mansoor N. Saleh, Chin‐Yu Lin, William D. Huse, Albert F. LoBuglio	154

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact